Complement in therapy and disease
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Complement is recognized as a key player in a wide range of normal as well as disease-related immune, developmental and homeostatic processes. Knowledge of complement components, structures, interactions, and cross-talk with other biological systems continues to grow and this leads to novel treatments for cancer, infectious, autoimmune- or age-related diseases as well as for preventing transplantation rejection. Antibodies are superbly suited to be developed into therapeutics with appropriate complement stimulatory or inhibitory activity. Here we review the design, development and future of antibody-based drugs that enhance or dampen the complement system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Complement: a key system for immune surveillance and homeostasis
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010) · Nature Immunology · doi:10.1038/ni.1923 · Cited by 3,654
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · cited 1×
“Fc glycosylation linked to the asparagine residue at amino acid position 297 is critical for the binding of IgG Fc to C1q and the induction of CDC and mutating this site strongly impacts C1q interaction (Nimmerjahn and Ravetch, 2008; Wright and Morrison, 1997).”
BackgroundInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449 · cited 2×
“Since the initial demonstration of n association between complement Factor H polymorphisms and MD (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 005; Klein et al., 2005), additional associations between AMD nd other complement component polymorphisms have become pparent (C2, C3, C7, Factor B, Factor D, Fa…”
BackgroundComplement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961 · cited 2×
“Since the initial demonstration of n association between complement Factor H polymorphisms and MD (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 005; Klein et al., 2005), additional associations between AMD nd other complement component polymorphisms have become pparent (C2, C3, C7, Factor B, Factor D, Fa…”
de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Self-citationSwain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Complement C3 variant and the risk of age-related macular degeneration
Yates, J. R. W., Sepp, T., Matharu, B. K., Khan, J. C., Thurlby, D. A., Shahid, H., Clayton, D. G., Hayward, C., Morgan, J., Wright, A. F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072618 · Cited by 829 · cited 1×
“…between AMD nd other complement component polymorphisms have become pparent (C2, C3, C7, Factor B, Factor D, Factor I, CFHR1/CFHR3) Ansari et al., 2013; Bergeron-Sawitzke et al., 2009; Dinu et al., 007; Fagerness et al., 2009; Francis et al., 2009; Stanton et al., 011; Yates et al., 2007).”
BackgroundTeeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
van Wamel, W. J. B., Rooijakkers, S. H. M., Ruyken, M., van Kessel, K. P. M., & van Strijp, J. A. G. (2006) · Journal of Bacteriology · doi:10.1128/jb.188.4.1310-1315.2006 · Cited by 579
Rituximab-Dependent Cytotoxicity by Natural Killer Cells
Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2862 · Cited by 434
Complement and Its Receptors: New Insights into Human Disease
Holers, V. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120154 · Cited by 430
A Dramatic Increase of C1q Protein in the CNS during Normal Aging
Stephan, A. H., Madison, D. V., Mateos, J. M., Fraser, D. A., Lovelett, E. A., Coutellier, L., Kim, L., Tsai, H.-H., Huang, E. J., Rowitch, D. H., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1333-13.2013 · Cited by 423 · cited 1×
“Also, in he normal aging mouse and human brain, C1q levels are increased ignificantly (Stephan et al., 2013).”
BackgroundVariation near complement factor I is associated with risk of advanced AMD
Fagerness, J. A., Maller, J. B., Neale, B. M., Reynolds, R. C., Daly, M. J., & Seddon, J. M. (2009) · European Journal of Human Genetics · doi:10.1038/ejhg.2008.140 · Cited by 357
Complement C1q Activates Canonical Wnt Signaling and Promotes Aging-Related Phenotypes
Naito, A. T., Sumida, T., Nomura, S., Liu, M.-L., Higo, T., Nakagawa, A., Okada, K., Sakai, T., Hashimoto, A., Hara, Y., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.047 · Cited by 320
Complement deficiencies and systemic lupus erythematosus
Truedsson, L., Bengtsson, A. A., & Sturfelt, G. (2007) · Autoimmunity · doi:10.1080/08916930701510673 · Cited by 315 · cited 1×
“Deficiencies within the early classical pathway components (C1q, C4 and C2) predispose for development of SLE, whereas complement also takes part in the auto-antibody inflammatory reaction in the disease leading to tissue and organ damage (Bryan and Wu, 2014; Truedsson et al., 2007).”
BackgroundFerrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305 · cited 1×
“The opportunities however are limited, as maximal terminal galactosylation of glycans (G2) was reported to increase CDC of the CD20 antibody rituximab up to a maximum of only 2-fold compared to the non-galactosylated (G0) antibody (Ferrara et al., 2006; Raju, 2008).”
BackgroundYehoshua, Z., Alexandre de Amorim Garcia Filho, C., Nunes, R. P., Gregori, G., Penha, F. M., Moshfeghi, A. A., Zhang, K., Sadda, S., Feuer, W., & Rosenfeld, P. J. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.044 · Cited by 299
Evidence for association between multiple complement pathway genes and AMD
Dinu, V., Miller, P. L., & Zhao, H. (2007) · Genetic Epidemiology · doi:10.1002/gepi.20204 · Cited by 58
Cited by
The immune system’s role in sepsis progression, resolution, and long-term outcome
Delano, M. J., & Ward, P. A. (2016) · Immunological Reviews · doi:10.1111/imr.12499 · Cited by 880
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
van de Donk, N. W. C. J., & Usmani, S. Z. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02134 · Cited by 354
Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353
Self-citationAvidity in antibody effector functions and biotherapeutic drug design
Oostindie, S. C., Lazar, G. A., Schuurman, J., & Parren, P. W. H. I. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00501-8 · Cited by 298
Self-citationBulla, R., Tripodo, C., Rami, D., Ling, G. S., Agostinis, C., Guarnotta, C., Zorzet, S., Durigutto, P., Botto, M., & Tedesco, F. (2016) · Nature Communications · doi:10.1038/ncomms10346 · Cited by 294
Metadata
- Authors
- Melis, J. P. M., Strumane, K., Ruuls, S. R., Beurskens, F. J., Schuurman, J., & Parren, P. W. H. I.
- Venue
- Molecular Immunology
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 67
- Issue
- 2
- Pages
- 117-130
- ISSN
- 0161-5890 (ISSN-L)
- OpenAlex
- W38898043
- Cited by
- 125
- References
- 21
- FWCI
- 7.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.